natgillin/translations-raw huggingface dataset:
binding of the antibody or fragment thereof to the first HER3 receptor in the presence of a HER3 ligand reduces ligand-dependent formation of a first HER3 receptor-second HER3 receptor protein complex in a cell which expresses first HER3 receptor and second HER3 receptor. 
vezanje protutijela ili njegovog fragmenta na prvi HER3-receptor u prisutnosti HER3-liganda, smanjuje tvorbu ovisnu o ligandu, proteinskog kompleksa od prvog HER3-receptora i drugog HER3-receptora, u stanici koja izražava prvi HER3-receptor i drugi HER3-receptor.
or a pharmaceutically acceptable salt thereof. 
Farmaceutski prihvatljiva sol spoja koji ima strukturu:
The method of claim 1, wherein the CD3 zeta signaling domain is encoded by a nucleic acid sequence comprising SEQ ID NO: 18. 
(iv) signalno područje 4-IBB je kodirano sekvencom SEQ ID NO: 17 i signalno područje CD3 zeta je kodirano sekvencom SEQ ID NO:18;
This embodiment may also include a foil strip 84 to couple fuel element 10 to the cellulose acetate tube 40 and to help extinguish the fuel. 
Ova realizacija može također uključivati vrpcu 84 od folije tako da se spoji gorivi element 10 za cjev 40 od acetata celuloze i da se pomogne gašenje goriva.
The glucocorticoid for the use of claim 3, wherein after a first and second dose of the CD3 binding domain for a first and second period of time, a third dose of the CD3 binding domain is administered, wherein the third dose exceeds the first and second dose. 
Glukokortikoid za uporabu iz patentnog zahtjeva 3, pri čemu se nakon prve 1 druge doze CD3 vezne domene tijekom prvog i drugog vremenskog razdoblja, primjenjuje treće doza CD3 vezne domene, pri čemu treća doza premašuje prvu i drugu dozu.
Therefore, the economical efficiency can be improved. The tire vulcanizer in the present invention further includes medium exhausting passages for exhausting the vulcanization gas discharged from the interiors of the bladders to an exterior, a tank provided in the medium exhausting passage, for storing the vulcanization gas discharged from the interiors of the bladders, and medium supplying paths respectively provided for the center mechanisms, for supplying the vulcanization gas in an interior of the tank to the interiors of the bladders, wherein at the time of at least one of the shaping and beginning of the vulcanization and the patterning, the vulcanization gas in the interior of the tank is supplied to the interiors of the bladders via the medium supplying paths. 
Vulkanizer u skladu s patentnim zahtjevom 1, nadalje obuhvaća: središnje ispušne prolaze (56, 66, 57) za izlazak vulkanizacijskog plina ispuštenog iz unutrašnjosti navedenih mjehura prema van; spremnik (70) predviđen u navedenom središnjem ispušnom prolazu, za pohranu vulkanizacijskog plina ispuštenog iz unutrašnjosti navedenih mjehura; 1 središnji opskrbni putovi (58, 59, 60) odgovarajuće predviđeni za navedene središnje mehanizme, za opskrbu vulkanizacijskog plina koji se nalazi u unutrašnjosti navedenog spremnika u unutrašnjosti navedenih mjehura, pri čemu je u vrijeme barem jednog od oblikovanja i početka vulkanizacije i modeliranja, vulkanizacijski plin koji se nalazi u unutrašnjosti navedenog spremnika dopremljen u unutrašnjosti navedenih mjehura putem središnjih opskrbnih putova.
A compound having the Formula III(A) or III(B): or a pharmaceutically acceptable salt thereof; wherein 
Spoj koji ima Formulu III(A) ili III(B): ili njegova farmaceutski prihvatljiva sol; naznačen time da L je veza ili C1-C10 alkilen;
an antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said fragment thereof is capable of reacting with the same antigen than its antibody counterpart, 
protutijelo, ili njegov fragment, izravno ili posredno kovalentno spojen s navedenim konjugatom, gdje navedeni njegov fragment može reagirati s istim antigenom kao odgovarajuće protutijelo, gdje navedeni konjugat sadrži:
The TGFB antagonist for use according to Claim 2, wherein said TGFB protein is TGFB-1, -2, -3, or a combination thereof. 
Antagonist TGFB za uporabu u skladu sa zahtjevom 2, naznačen time što navedeni TGFB protein je TGFB-1, -2, -3, ili njihova kombinacija.
14, 15 and 16 and in its light chain variable region L-CDR1, L-CDR2 and L-CDR3 shown in SEQ ID NOs. 
14, 15 1 16, a u svom varijabilnom području lakog lanca L-CDR1, L-CDR2 i L-CDR3, prikazane u SEQ ID NO.
The oil according to claim 2 wherein, in the case a single flavouring is used, the amount of flavouring added to the product is comprised of between 0.02% and 0.1% by weight, with respect to the weight of the other components. 
Ulje prema jednom od zahtjeva 4 do 11, naznačeno time, da je aromatski dodatak u sadržaju od 0,02 do 0,1 masenih %, poželjno od 0,03 do 0,07 masenih %, u odnosu na masu ostalih sastojaka, u slučaju uporabe samo jednog aromatskog dodatka u proizvodu.
Macrocapsule 52 and fuel element 10 may be united by a conventional cigarette paper 47, as illustrated in the drawing, by a perforated ceramic paper, or a foil strip. 
Makrokapsula 52 i gorivi element 10 mogu biti ujedinjeni pomoću konvencionalnog cigaret papira 47, kao što je ilustrilano na crtežu, pomoću perforiranog keramičkog papira ili vrpce od folije.
An isolated nucleic acid encoding a humanized anti-beta7 antibody comprising: 
Izolirana nukleinska kiselina, naznačena time, da kodira humanizirano protutijelo anti-beta7, te obuhvaća;
The use of a pharmaceutical combination according to claim 8, comprising an atypical antipsychotic drug selected from the group consisting of olanzapine or risperidone and a GlyT1 receptor antagonist which is and pharmaceutically acceptable acid addition salts thereof, as well as enantiomeric forms thereof. 
Uporaba farmaceutske kombinacije prema zahtjevu 8, naznačena time, da se koristi kombinacija koja obuhvaća netipičan antipsihotički lijek odabran iz skupine koju čine olanzapin ili risperidon te antagonist receptora GlyT1 koji je sljedeći:
The use of a composition comprising a hollow glucan particle or cell wall particle encapsulating a terpene component according to any one of claims 1 to 10 in the manufacture of a medicament for the prevention or treatment of an infection caused by a micro-organism. 
Sastav temeljem bilo kojeg od zahtjeva 1 do 43 za uporabu kod sprječavanja ili liječenja zaraze kod pacijenta ili biljke. Uporabu sastava temeljem bilo kojeg od zahtjeva 1 do 43 kod proizvodnje lijeka za liječenje zaraze kod pacijenta.
disconnecting the failed card from the controlled plant (E) and connecting the corresponding connector to a protection bus, 
– odvajanja pokvarene kartice od upravljane opreme (E) i spajanja odgovarajućeg konektora sa zaštitnom sabirnicom;
• when RCG1 represents a maleimido or haloacetamido function or a -Cl group, RCG2 represents a -SH group; 
* kada RCGI predstavlja maleimido ili haloacetamido funkciju ili skupinu -Cl, RCG2 predstavlja skupinu - SH;
An electrically heated smoking system according to any of claims 1 to 5, wherein the one or more electrically conductive tracks are on the outside of the tube of electrically insulating substrate. 
Električno grijani sustav za pušenje u skladu s patentnim zahtjevom 1, 2 1li 3, naznačen time što se jedna ili više električno vodljivih tračnica (203) nalazi s vanjske strane cijevi od električno izolirajuće podloge (201).
In one embodiment the additional antigens are antigens derived from a bacterium selected from the group consisting of S. pneumoniae, H. influenzae, N. meningitidis, E. coli, M. cattarhalis, tetanus, diphtheria, pertussis, S. epidermidis, enterococci, S. aureus, and Pseudomonas aeruginosa . 
Imunogeni pripravak u skladu s patentnim zahtjevom 26, naznačen time što su dodatni antigeni antigeni dobiveni iz bakterije koju se bira iz skupine koju čine 5. pneumoniae, H. influenzae, N.meningitidis, E. coli, M. cattarhalis, tetanus, difterija, hripavac, S. epidermidis, enterokoki, S.aureus i Pseudomonas aeruginosa.
A compound of formula (II) as claimed in claim 3, for manufacture of a medicament for treatment of a disorder of central nervous system related to or affected by the 5-HT6 receptors. 
Spoj formule (ID prema patentnom zahtjevu 3, za proizvodnju lijeka za liječenje poremećaja središnjeg živčanog sustava povezanog s ili pogođenog s 5-HT4 receptorima.
#13. A delayed release drug formulation according to any of the preceding aspects, wherein the third polymeric material is soluble in water independently of pH. 
Formulacija lijeka s produljenim oslobađanjem za koju se traži zaštita patentom u bilo kojem od prethodnih patentnih zahtjeva, pri čemu je treći polimerni materijal topiv u vodi neovisno od pH.
The polypeptide of claim 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:66 residues 1-378. 
Polipeptid iz patentnog zahtjeva 2, koji sadrži aminokiselinsku sekvencu u skladu sa SEK ID BR:1 ostaci 1-567.
Fig. 7 shows the flushing unit 5 with the fluid inlet 16 and the fluid outlet 17, the inlet being in contact with the fluid channel 24 and the outlet being in contact with the fluid channel 25. 
Slika 7 prikazuje jedinicu za ispiranje 5 s ulaznim otvorom za fluid 16 i izlaznim otvorom za fluid 17, pri čemu je ulazni otvor spojen s kanalom za fluid 24, a izlazni otvor je spojen s kanalom za fluid 25.
The pump will be located 8 feet away from the controller 80. 
Pumpa se postavlja na oko 2,5 m od kontrolora 80.
has a genetic mutation in a gene other than the gene encoding factor VIII which is linked with an increased risk of developing an inhibitory immune response. 
(f) ima genetsku mutaciju u genu koji nije gen koji kodira faktor VIII koji je povezan s povećanim rizikom za razvoj inhibicijskog imunog odgovora.
is provided with a catch located closer to the proximal end than to the distal end of the corresponding latch, such that the pivoting of any one of the at least first and second latches about its corresponding hinge from its respective idle position to its respective fixing position reduces a distance separating the catch thereof from the centroid of the central opening; 
opremljen je sredstvima za zahvaćanje (33, 33a) koja se nalaze bliže proksimalnom kraju nego distalnom kraju zasuna, tako da se okretanje bilo kojeg od prvih i drugih zasuna (32) oko odgovarajućeg zgloba (36) iz odgovarajućeg položaja praznog hoda u odgovarajući položaj za pričvršćenje smanjuje udaljenost koja razdvaja sredstva za zahvaćanje (33, 33a) od središta središnjeg otvora.
The method of claim 1, further comprising fusion-registration of (a) the at least one irradiated readout image with, (b) the at least one control readout image with, (c) at least one three-dimensional dose distribution calculated by the patient-specific radiotherapy treatment plan. 
Postupak prema patentom zahtjevu 1, naznačen time što nadalje sadrži usporedbu najmanje jedne slike očitavanja s najmanje jednom trodimenzionalnom raspodjelom doze koja je izračunata pomoću sustava za planiranje radioterapijskog liječenja.
A donor vector comprising first and second DNA sequences; wherein the first sequence is homologous to a third sequence and the second sequence is homologous to a fourth sequence; and wherein the third and fourth sequences are chromosomal EPSPS DNA sequences, further wherein the near edges of third and fourth sequences are contiguous or are separated by at least 1 nucleotide pair and optionally wherein the vector further comprises a fifth sequence, wherein the fifth sequence: 
Donatorski vektor, naznačen time, da obuhvaća prvu i drugu sekvencu DNK; pri čemu je prva sekvenca homologna trećoj sekvenci, a druga sekvenca je homologna četvrtoj sekvenci; te time, da su treća 1 četvrta sekvenca kromosomske EPSPS sekvence DNK, dok su nadalje bliži bridovi treće i četvrte sekvence granični ili su odvojeni pomoću najmanje jednog nukleotidnog para i opcijski, gdje vektor nadalje obuhvaća petu sekvencu, pri čemu je peta sekvenca:
The antibody of claim 1, wherein the antibody exhibits greater than 50% inhibition of Mac-1 binding to the fibrin or fibrinogen YC domain. 
Protutijelo iz patentnog zahtjeva 1, pri čemu protutijelo pokazuje više od 20% inhibicije vezanja Mac-1 za YC domenu fibrina ili fibrinogena.
Template device, as claimed in claim 1, characterized in that the lower part of the template device (1) is orthogonal to the direction of feed of the slab (4) and forms a base or bracket (5) which is provided with coupling means for coupling with the supporting frame (6) of the slab border polishing machine in the feed area of the slab itself. 
Stroj za poliranje prema prethodnom zahtjevu, naznačen time, da je donji dio šablone (1) ortogonalan na smjer ulaska ploče (4) i oblikuje bazu ili podupirač (5) koji je opremljen sredstvima za spajanje koja dozvoljavaju spregu s nosivim okvirom (6) stroja za poliranje rubova ploča u području ulaska same ploče.
According to a preferred configuration, the device is distinguished by the fact that the second housing connecting unit is formed by an abutment element, which is mounted, in particular releasably mounted, on the opposite walls and has a through-clearance. 
naznačena time da - = je druga spojna jedinica kućišta (24) oblikovana pomoću potpornog elementa (40), koji je montiran, naročito odvojvo montiran, na suprotnim stjenkama (26, 28) i ima prolazni zazor (42).
The use of any one of claims 1-3, wherein the nucleosidic component is connected to the monosaccharide residue via a nucleobase of a building block present in a nucleic acid molecule, particularly via a terminal building block present in a nucleic acid molecule. 
Uporaba u skladu s bilo kojim od patentnih zahtjeva 1-3, pri čemu je nukleozidna komponenta vezana za talog monosaharida pomoću nukleobaze gradbenog bloka prisutne u molekuli nukleinske kiseline, posebice pomoću terminalnog gradbenog bloka prisutnog u molekuli nukleinske kiseline.
is selected from F or H, is selected from H, CH3, halogen, dimethylamino, pyridin-4yl, phenyl, 2- or 4- (halo)penyl, 2- or 4-(trifluoromethyl)phenyl and 2- and/or 4-halobenzyloxyfor use in the prevention and/or treatment of a disease associated with the activity of TRPM8 selected from the group consisting of pain, itch, cold-induced respiratory disorders, ischaemia, painful bladder syndrome, interstitial cystitis, detrusor overactivity, urinary incontinence, neurogenic detrusor overactivity, idiopathic detrusor overactivity, benign prostatic hyperplasia, stroke, neurodegeneration and psychiatric disorders. 
R; je izabran od F ili H, R, je izabran od H, CH,, halogena, dimetilamino, piridin-4-ila, fenila, 2- ili 4- (halo)penila, 2- ili 4- (trifluorometil)fenila i 2- i/ili 4-halobenziloksi za upotrebu u prevenciji i/li liječenju bolesti povezane s aktivnošću TRPMB8 izabrane iz grupe koja se sastoji od boli, svraba, respiratornih poremećaja induciranih prehladom, ishemije, sindroma bolnog mjehura, intersticijalnog cistitisa, prekomjerne aktivnosti detruzora, urinarne inkotinencije, neurogene prekomjerne aktivnosti detruzora, idiopatske prekomjerne aktivnosti detruzora, benigne hiperplazije prostate, moždanog udara, neurodegeneracije i psihijatrijskih poremećaja.
Device according to claim 29, characterized in that the planing equipment (63) has at least one rotary machining tool (63"). 
Uređaj u skladu s patentnim zahtjevom 29, naznačen time, što oprema za ravnanje (63) ima najmanje jedan rotacijski alat za obradu (63").
Method for modifying a (co)polymer by transporting the packaged formulation according to claim 2 to a polymer modification unit and introducing the formulation into the process. 
Postupak modificiranja (ko)polimera transportom pakirane formulacije u skladu s patentnim zahtjevom 2, naznačen time što se sastoji u transportu u jedinicu za modificiranje polimera i uvođenje formulacije u process.
Referring to fig. 
Prema sl.
An aerosol of an aqueous solution, the solution comprising from 80 mg/ml to 120 mg/ml levofloxacin or ofloxacin and from 160 mM to 220 mM of a divalent or trivalent cation, wherein the solution has a pH from 5 to 7 and an osmolality from 300 mOsmol/kg to 500 mOsmol/kg, for use in the treatment of a pulmonary infection in a human, wherein the levofloxacin or ofloxacin is administered in a dose of 20 to 300 mg twice daily. 
PATENTNI ZAHTJEVI M» Aerosol vodene otopine, otopina koja od 80 mg/ml do 120 mg/ml levofloksacina ili ofloksacina i od 160 mM do 220 mM dvovalentnog ili trovalentnog kationa, pri čemu otopina ima pH od 5 do 7 1 osmolalnost od 300 mOsmol/kg do 500 mOsmol/kg, za uporabu u liječenju plućne infekcije kod čovjeka, pri čemu se levofloksacin ili ofloksacin daju u dozi od 20 do 300 mg dvaput dnevno.
The present invention is based in part on the recognition that carbohydrate derivatives of rapamycin in which the rapamycin molecule is modified at the 31- and/or 42- position, as defined by the current Chemical Abstracts nomenclature, by attaching monosaccharide(s), oligosaccharide(s) or pseudasugars, have similar or enhanced pharmacokinetic and/or pharmacodynamic profiles compared to rapamycin. 
Bit izuma Ovaj izum dijelom se temelji na činjenici da ugljikohidratni derivati rapamicina u kojima je molekula rapamicina modificirana na položajima 31 i/ili 42, kako je definirano važećom nomenklaturom po Chemical Abstracts, dodatkom monosaharida, oligosaharida ili pseudošećera, imaju sličan ili poboljšan farmakokinetički i/ili farmakodinamički profil u usporedbi s rapamicinom.
a spr0867 antigen comprising an amino acid sequence: (a) having 80% or more identity to SEQ ID NO: 8; and/or (b) comprising a fragment of at least 10 consecutive amino acids, comprising an epitope of SEQ ID NO: 8; 
antigen spr0867 koji sadrži aminokiselinski slijed: (a) koji je 80% ili više identičan SEQ ID NO: 8; i/ili (b) sadrži fragment od najmanje 10 uzastopnih aminokiselina, koji sadrži epitop iz SEQ ID NO: 8;
A peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 214, 196, 202, 210, 213, 217 and 223 in which 1 or 2 amino acids are substituted, or added, wherein said peptide induces a cytotoxic T cell specific to a cell expressing KNTC2. 
Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO:376 i 379, u kojima su 1 ili 2 aminokiseline zamijenjene, gdje navedeni peptid inducira citotoksičnu T-stanicu specifičnu za stanicu koja eksprimira EphA4.
The pharmaceutical composition according to claim 11, further comprising one or more other suitable therapeutic agents useful in the treatment of the aforementioned disorders including: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, anti-pancreatic agents, lipid lowering agents, anorectic agents, memory enhancing agents, anti-dementia agents, or cognition promoting agents, appetite suppressants, treatments for heart failure, treatments for peripheral arterial disease and anti-inflammatory agents. 
Farmaceutska kompozicija prema patentnom zahtjevu 31, koja dalje sadrži jedno ili više drugih pogodnih terapeutskih sredstava izabranih od: anti-dijabetičkih sredstava, anti-hiperglikemijskih sredstava, anti-hiperinsulinemijskih sredstava, anti-retinopatskih sredstava, anti-neuropatskih sredstava, anti-nefropatijski sredstava, anti-aterosklerotičnih sredstava, anti-ishemijskih sredstava, anti-hipertenzivnih sredstava, sredstava protiv debljine, anti-dislipidemijskih sredstava, anti-hiperlipidemijskih sredstava, anti-hipertrigliceridemijskih sredstava, anti-hiperkolesterolemijskih sredstava, anti-restenotičnih sredstava, sredstava za snižavanje lipida, anorektičkih sredstava i supresanata apetita.
first and second magnetically permeable segments separated by an intermittently arranged magnetically insulating barrier; and 
prvi i drugi magnetski permeabilni segment odvojene pomoću naizmjenično postavljenih magnetskih izolacijskih barijera; te
An assembly for implanting a balloon-expandable prosthetic aortic heart valve in a patient's body, comprising: 
Sklop za ugradnju protetskog aortnog zgloba koji se može proširiti u balon u tijelu pacijenta, koji sadrži:
wherein R1 and R4 are as defined for the compound of formula (4). 
(4a) gdje su RI i R4 kao što je definirano za spoj sa formulom (4).
Process according to any of Claims 1 to 4, wherein the water-soluble calcium compound is selected from calcium chloride, calcium nitrate, calcium formate, calcium acetate, calcium bicarbonate, calcium bromide, calcium carbonate, calcium citrate, calcium chlorate, calcium fluoride, calcium gluconate, calcium hydroxide, calcium oxide, calcium hypochlorite, calcium iodate, calcium iodide, calcium lactate, calcium nitrite, calcium oxalate, calcium phosphate, calcium propionate, calcium silicate, calcium stearate, calcium sulphate, calcium sulphate hemihydrate, calcium sulphate dihydrate, calcium sulphide, calcium tartrate, calcium aluminate, tricalcium silicate and/or dicalcium silicate. 
Uporaba prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time što je spoj kalcija topiv u vodi izabran od kalcij klorida, kalcij nitrata, kalcij formata, kalcij acetata, kalcij bikarbonata, kalcij bromida, kalcij karbonata, kalcij citrata, kalcij klorata, kalcij fluorida, kalcij glukonata, kalcij hidroksida, kalcij oksida, kalcij hipoklorita, kalcij jodata, kalcij jodida, kalcij laktata, kalcij nitrita, kalcij oksalata, kalcij fosfata, kalcij propionata, dikalcij silikata, kalcij stearata, kalcij sulfata, kalcij sulfat hemihidrata, kalcij sulfat dihidrata, kalcij sulfida, kalcij tartarata, kalcij aluminata, kalcij silikata i/ili dikalcij silikata.
The mixture was heated at 70°C for one hour. 
Smjesa je potom zagrijavana na 70 "C kroz I sat.
The monoclonal antibody or antigen-binding portion thereof of any one of claims 1-2, wherein the antibody is capable of inhibiting cancer growth in a mammal, preferably a human patient. 
Monoklonsko antitijelo ili njegov dio koji se veže na antigen sukladno zahtjevu 1, naznačeno time, da je sisavac ljudski pacijent.
Oral pharmaceutical dosage form comprising at least buprenorphine or a pharmaceutically acceptable salt thereof wherein the dosage form releases substantially all of buprenorphine or said pharmaceutically acceptable salt within less than 2 minutes after oral, preferably sublingual, application of the dosage form. 
PATENTNI ZAHTJEVI Oralni farmaceutski dozirni oblik koji sadrži barem buprenorfin ili njegovu farmaceutski prihvatljivu sol gdje dozirni oblik oslobađa u biti sav buprenorfin ili njegovu farmaceutski prihvatljivu sol za manje od 2 minute nakon oralne, poželjno sublingvalne, primjene dozirnog oblika.
Test substance or vehicle are given either at 60 min after starting the stimulation (intravenous and intraduodenal dosing, 1 mil/kg), or 2 h before starting the stimulation (oral dosing, 5 ml/kg, gastric cannula closed). 
Testirana tvar ili prijenosnik su davani ili 60 min nakon početka stimulacije (intravenozno i intrađuodenalno s dozom od I ml/kg), ili 2 h prije početka stimulacije (oralna doza: 5 ml/kg; želučana cjevčica je zatvorena).
The hydrogenation mixture was filtered, and the solvent was removed under reduced pressure. 
HR P20070194 T3 smjesa se filtrira, potom se ukloni otapalo uz sniženi tlak.
Finally, 45 g of magnesium stearate were admixed to obtain a compression mixture. 
Poslije toga smjesi je uz miješanje dodano 45 g magnezija stearata čime je dobivena kompresijska smjesa.
The pharmaceutical composition of numbered paragraph 40 wherein the composition has a baseline peroxide value not greater than 5 Meq/kg and upon storage of the composition at 25 °C and 60% RH for a period of 6 months, the composition has a second peroxide value not greater than 8 Meq/kg. 
(a) pripravak ima osnovnu peroksidnu vrijednost ne veću od 5 Meq/kg i nakon skladištenja pripravka na 25 *C i 60% RH kroz period od 6 mjeseci, pripravak ima drugu peroksidnu vrijednost ne veću od 8 Meq/kg,